TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2037113
Drug: GnRH‐a and
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH‐a and hMG for IVF treatment with extended follicle growth by 1 day
Study: 7125264
Drug: Midazolam-Ketamine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam-Ketamine combination (0.15 mg/kg midazolam and 0.75 mg/kg ketamine)
Study: 30882604
Drug: Firibastat (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Firibastat (250 mg b.i.d. for 1 week, uptitrated to 500 mg b.i.d. for 3 weeks)
Study: 28555206
Drug: Conical connection
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conical connection implants
Study: 28555206
Drug: Internal hex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal hex connection implants
Study: 26686406
Drug: Elotuzumab 10
Normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Elotuzumab 10 mg/kg plus lenalidomide (25 mg) and dexamethasone (40 mg)
Study: 26686406
Drug: Elotuzumab 20
Normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Elotuzumab 20 mg/kg plus lenalidomide (25 mg) and dexamethasone (40 mg)
Study: 19747744
Drug: Celecoxib (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (2 x 400 mg/day)
Study: 12626436
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human IL-6 infusion (3 hours)
Study: 11298543
Drug: Famciclovir (FCV)
Normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Famciclovir (FCV) 125 mg twice daily for 5 days
Study: 11298543
Drug: Aciclovir (ACV)
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aciclovir (ACV) 200 mg five times daily for 5 days
Study: 8497826
Drug: Frusemide (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide (5, 10, and 20 mg)
Study: 2447411
Drug: SLOx (slow
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLOx (slow release oxprenolol) administered in a single evening dose for 7 days
Study: 2447411
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered for 7 days
Study: 21178422
Drug: Procalcitonin (PCT)
Normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin (PCT) guidance for antibiotic therapy
Study: 18005195
Drug: Enteral nutrition
Normalized name: ENTERAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral nutrition (EG) - 3 cups of Clinutren fruit, 2 boxes of OPD Elemental 028 extra, 2 cups of OPD Peptamen, 1000 ml isotonic cristalloid solution, allowed to drink up to 1000 ml of tea or water per 24 h
Study: 18005195
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (PG) - 1250 ml Nutriflex lipid basal intravenously, 1000 ml isotonic cristalloid solution, allowed to drink up to 1000 ml of tea or water per 24 h
Study: 18005195
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (PG)
Study: 350232
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg daily
Study: 350232
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg daily
Study: 30757926
Drug: Cervicothoracic junction
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cervicothoracic junction manual therapy
Study: 30757926
Drug: Upper-cervical manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upper-cervical manual therapy
Study: 19370038
Drug: Flaxseed lignan
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed lignan complex (543 mg/day in a 4050 mg complex)
Study: 12860938
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m2 and cisplatin 75 mg/m2
Study: 10670374
Drug: Self-instructional module
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-instructional module (SIM) on care of child receiving Oxygen Therapy
Study: 2568663
Drug: Minor tranquilizer
Normalized name: Vinca minor extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minor tranquilizer
Study: 358760
Drug: Pindolol once
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pindolol once daily
Study: 358760
Drug: Pindolol twice
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pindolol twice daily
Study: 27498443
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amoxicillin and metronidazole (for 7 days)
Study: 17900989
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training (a combination of aerobic and resistance training, three times per week for 24 weeks)
Study: 14587010
Drug: Blood-pool contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood-pool contrast media (NC100150, 2 ml/kg body weight)
Study: 8708369
Drug: Aerosolized pentamidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized pentamidine (300 mg/4 weeks)
Study: 8708369
Drug: Orally trimethoprim‐sulfamethoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally trimethoprim‐sulfamethoxazole (320‐1600 mg/day)
Study: 1752294
Drug: Aspirin 300
Normalized name: aspirin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 300 mg three times a day (t.d.s.)
Study: 1752294
Drug: Aspirin 300
Normalized name: aspirin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 300 mg three times a day (t.d.s.) with dipyridamole 100 mg t.d.s.
Study: 7235320
Drug: Flunisolide intranasal
Normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flunisolide intranasal solution (200 microgram/day) combined with intrabronchial flunisolide (1 mg/day)
Study: 7235320
Drug: Flunisolide intranasal
Normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flunisolide intranasal solution (200 microgram/day) combined with beclomethasone dipropionate bronchial aerosol (400 microgram/day)
Study: 28494850
Drug: Traditional Persian
Normalized name: PERUVIAN BALSAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Persian medicine preparation of Alcea digitata and Malva sylvestris
Study: 17467203
Drug: E2/DRSP (estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2/DRSP (estradiol 1 mg/drospirenone 2 mg)
Study: 8093363
Drug: d4T (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: d4T (2 mg/kg/day)
Study: 9361572
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous heparin
Study: 3531862
Drug: Intermittent subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent subcutaneous heparin
Study: 30280654
Drug: Wearable cardioverter-defibrillator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wearable cardioverter-defibrillator plus guideline-directed therapy
Study: 30280654
Drug: Guideline-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-directed therapy only (control group)
Study: 26663817
Drug: DHEA (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (25 mg three times a day for 12 weeks)
Study: 25591511
Drug: Traditional medicinal
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional medicinal treatment
Study: 22460067
Drug: Maintenance dose
Normalized name: Firmagon 80mg Powder for Injection Maintenance Dose Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance dose of 50 μg
Study: 22460067
Drug: Maintenance dose
Normalized name: Firmagon 80mg Powder for Injection Maintenance Dose Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance dose of 100 μg
Study: 18174779
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II receptor blocker-based program
Study: 18174779
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blocker-based treatment regimen
Study: 18174779
Drug: Multiple-drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-drug therapy (therapy with > or =2 medications)
Study: 12872679
Drug: Cetirizine (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (daily treatment for 3 years)
Study: 12872679
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily treatment for 3 years)
Study: 7587910
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid ethyl (EPA-E) 900 mg/day
Study: 120541
Drug: Alcohol (1
Normalized name: POLYVINYL ALCOHOL (18000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (1 g/kg in orange juice)
Study: 120541
Drug: Alcohol (1
Normalized name: POLYVINYL ALCOHOL (18000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (1 g/kg in orange juice) plus CBD (200 mg capsule)
Study: 120541
Drug: CBD (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD (200 mg capsule)
Study: 120541
Drug: Placebo (glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (glucose capsule and orange juice)
Study: 25567214
Drug: Gabapentin 500
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 500 mg
Study: 22679719
Drug: Shencao Tongmai
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shencao Tongmai Granule (STG) plus Western medicine (WM) treatment
Study: 22679719
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus Western medicine (WM) treatment
Study: 9809893
Drug: Bivalirudin (direct
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin (direct thrombin inhibitor)
Study: 2490827
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment for hypertension (including thiazide-like diuretic agents)
Study: 946209
Drug: Rabies vaccine
Normalized name: RABIES VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabies vaccine produced in human diploid cell culture (WI-38)
Study: 946209
Drug: Rabies vaccine
Normalized name: RABIES VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabies vaccine produced in hamster kidney-cell culture
Study: 7377574
Drug: Naloxone, 8
Normalized name: Buprenorphine-Naloxone, 8 mg-2 mg sublingual film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone, 8 mg
Study: 7377574
Drug: Naloxone, 4
Normalized name: Buprenorphine-Naloxone, 4 mg-1 mg sublingual film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone, 4 mg
Study: 26733360
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Treatment for Insomnia (CBT-I) followed by Positive Airway Pressure (PAP)
Study: 26733360
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Treatment for Insomnia (CBT-I) and Positive Airway Pressure (PAP) administered concurrently
Study: 24742739
Drug: Everolimus (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (5 mg/day) plus trastuzumab (2 mg/kg) and vinorelbine (25 mg/m(2))
Study: 17924890
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine 2% combined with general anaesthesia
Study: 9568921
Drug: First trimester
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First trimester other illicit drug use
Study: 2197635
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 1 g xantinolnicotinate (Complamin)
Study: 320808
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg of 2% plain prilocaine
Study: 320808
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg of 2% plain mepivacaine
Study: 12843161
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (200 mg)
Study: 10983343
Drug: Oxytocin (parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (parenteral administration)
Study: 1583340
Drug: Ivermectin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (1 mg clearing dose followed by either one or two 200 micrograms/kg doses)
Study: 1583340
Drug: Diethylcarbamazine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethylcarbamazine (12 daily 6 mg/kg doses)
Study: 3905392
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II infusion (7.5 ng X kg‐1 X min‐1)
Study: 3905392
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution infusion (control)
Study: 30597550
Drug: Parent-mediated treatment
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-mediated treatment
Study: 29694316
Drug: Mindfulness-based stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based stress reduction (MBSR) + Treatment as Usual (TAU)
Study: 26444907
Drug: Calcipotriene 0.005%
Normalized name: CALCIPOTRIENE 0.005% OINT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriene 0.005% and betamethasone dipropionate 0.064% ointment
Study: 18499730
Drug: Acute intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Acute intra-arterial vitamin C administration (24 mg min(‐1))
Study: 18499730
Drug: Chronic oral
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic oral vitamin C supplementation (500 mg day(‐1))
Study: 12915645
Drug: Biphasic association
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biphasic association of 40/30 micro g ethinyl estradiol (EE) and 25/125 micro g desogestrel (DSG)
Study: 12915645
Drug: Monophasic association
Normalized name: Monobasic Potassium Phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monophasic association of 35 micro g EE and 2 mg cyproterone acetate (CPA)
Study: 11382647
Drug: Daily disposable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily disposable contact lenses
Study: 8906382
Drug: Conventional daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional daily wear contact lenses
Study: 1796228
Drug: DEC 6
Normalized name: Zodryl DEC 60 Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC 6 mg/kg
Study: 6191906
Drug: 1 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/day ISO for 7 days
Study: 6191906
Drug: 4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/day ISO for 7 days
Study: 6191906
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment for 7 days
Study: 30772754
Drug: Intravenous Immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Immunoglobulin (IVIG)
Study: 24485800
Drug: Modafinil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (200 mg) combined with cognitive training
Study: 22409711
Drug: UVA1 (moderate
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVA1 (moderate dose)
Study: 22409711
Drug: UVA1 (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVA1 (low dose)
Study: 22409711
Drug: UVA1 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVA1 (both doses)
Study: 12171430
Drug: TML liquid
Normalized name: BTL-TML-COVID
DrugBank: Thimerosal (DB11590)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TML liquid diet (20 g/d)
Study: 12171430
Drug: Soybean oil
Normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean oil liquid diet (20 g/d)
Study: 9854601
Drug: DDAVP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDAVP plus behavioral therapy
Study: 9854601
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy plus placebo
Study: 8570776
Drug: Naltrexone 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 40 mg
Study: 1319874
Drug: Cimetidine 400mg
Normalized name: CIMETIDINE 400MG TAB
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine 400mg 3 times daily for 8 days
Study: 6370028
Drug: Diazepam (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (10-20 mg)
Study: 6370028
Drug: Triflupromazin (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triflupromazin (10-20 mg)
Study: 6370028
Drug: Pethidin (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidin (50-100 mg)
Study: 6370028
Drug: Buprenorphin (0.15-0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphin (0.15-0.3 mg)
Study: 6370028
Drug: Droperidol (2.5-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (2.5-5 mg)
Study: 22035500
Drug: Small-bowel capsule
Normalized name: Smallpox (Vaccinia) Vaccine, Live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-bowel capsule endoscopy
Study: 22035500
Drug: Adequate antiallergic
Normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adequate antiallergic treatment
Study: 17490956
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (6 g EPA+DHA/d) for either 7, 14, or 21 days before surgery
Study: 17490956
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil (10 mL/d for 21 days before surgery)
Study: 17490956
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (10 mL/d for 21 days before surgery)
Study: 11966665
Drug: Tezosentan infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tezosentan infusion at 100 mg h(‐1) for 6 h (study A)
Study: 11966665
Drug: Tezosentan infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tezosentan infusion at 5 mg h(‐1) for 72 h (study B)
Study: 9150773
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% with adrenaline (30 ml)
Study: 9150773
Drug: Saline (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (30 ml)
Study: 3440106
Drug: Erythromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (500 mg three times daily for 10 days)
Study: 3440106
Drug: Control state
Normalized name: CLOZAPINE (GOLDEN STATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control state (single dose of CBZ 400 mg)
Study: 29462657
Drug: Serlopitant 1
Normalized name: Serlopitant
DrugBank: Serlopitant (DB12973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serlopitant 1 mg
Study: 27914504
Drug: Ezetimibe (Ez)
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe (Ez) 10 mg/d with Simvastatin (S) 40 mg/d (Ez/S)
Study: 27914504
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with Simvastatin 40 mg/d (P/S)
Study: 20105282
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of AQ and SP (AQ+SP)
Study: 18086006
Drug: Sex steroid
Normalized name: Sex steroid binding globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sex steroid deficiency (‐T, ‐E)
Study: 1347955
Drug: 2.4 mg
Normalized name: pectin 2.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 mg FTC nicotine cigarettes
Study: 1347955
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg FTC nicotine cigarettes
Study: 3920770
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg 4 times a day
Study: 3920770
Drug: Misoprostol high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol high-dose (200 micrograms 4 times a day)
Study: 30486574
Drug: Dexmedetomidine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (loading dosage 0.5 μg/kg, continuous infusion 0.2 μg·kg(‐1)·h(‐1) until 30 minutes before the end of operation)
Study: 27272161
Drug: Fluticasone 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone 125 μg + formoterol 5 μg in the same device
Study: 27272161
Drug: Fluticasone 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone 125 μg + formoterol 12 μg as needed
Study: 27272161
Drug: Fluticasone 250
Normalized name: FLUTICASONE 250MCG/BLSTR PO INH ROTADISK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone 250 μg + formoterol 12 μg as needed
Study: 20035039
Drug: Levofloxacin (LVFX)
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin (LVFX) 500 mg single oral dose
Study: 15853102
Drug: Rotating rubber
Normalized name: Aspergillus ruber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotating rubber cup with prophylaxis gel (PG)
Study: 7485938
Drug: Spinal anaesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anaesthesia and midazolam (0.05 mg/kg)
Study: 2249377
Drug: Adinazolam mesylate
Normalized name: mesylate
DrugBank: Adinazolam (DB00546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adinazolam mesylate (10, 30, 50 mg)
Study: 2249377
Drug: NDMAD mesylate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: NDMAD mesylate (10, 30, 50 mg)
Study: 30621746
Drug: Reduced-dose TNF
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Reduced-dose TNF inhibitors (approximately half of the full dose)
Study: 27702622
Drug: DSAEK with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSAEK with active air infusion system
Study: 27702622
Drug: DSAEK without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DSAEK without active air infusion system